Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2LPAPI in Genital HR-HPV Infections
NCT04232917Phase 4Recruiting
- Sponsor
- Labo'Life
- Start
- Oct 2020
- Primary completion
- Oct 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in human papillomavirus infection comparing 2LPAPI® arm with Placebo arm (2 arms). Primary endpoint: Clearance of genital HR-HPV infections at 12 months. Started Oct 2020; status: recruiting.
02
Drugs
2LPAPI
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04232917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232917.